017 Define cirrhosis, classify cirrhosis. Describe aetiopathogenesis, 20 Novem 2 PIMS morphology, clinical findings and complications of Alcoholic ber cirrhosis. L.Q 2017 Describe aetiopathology of cirrhosis of liver. 20 March 2 MS UNIVERS L.Q 2

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Loading Image
Reading File
Loading Image
Reading File
I now have comprehensive content to write a detailed long-question answer. Let me compile it.

Cirrhosis of the Liver - Comprehensive Long Question Answer


1. DEFINITION

Cirrhosis is the diffuse transformation of the entire liver into regenerative parenchymal nodules surrounded by dense bands of fibrous (collagen-rich) scar tissue, resulting in distortion of hepatic architecture and vascular disruption. It represents the morphologic end point of most chronic liver diseases and is associated with varying degrees of hepatocellular dysfunction.
"Cirrhosis refers to the diffuse transformation of the liver into regenerative parenchymal nodules surrounded by fibrous bands."
  • Robbins & Kumar Basic Pathology

2. CLASSIFICATION OF CIRRHOSIS

A. Morphological Classification

TypeNodule SizeCommon Causes
Micronodular (Laennec's cirrhosis)Nodules <3 mm, uniform sizeAlcohol, biliary obstruction, hemochromatosis
Macronodular (post-necrotic)Nodules >3 mm, variable sizeViral hepatitis (HBV, HCV), autoimmune
MixedBoth micro- and macronodulesMany causes; micronodular may evolve into macronodular

B. Aetiological Classification

CategoryExamples
Alcohol-associatedChronic alcohol use disorder
ViralChronic HBV, HCV infection
MetabolicMASLD (formerly NAFLD), Wilson's disease, haemochromatosis, Alpha-1 antitrypsin deficiency
BiliaryPrimary biliary cholangitis, primary sclerosing cholangitis, secondary biliary cirrhosis
AutoimmuneAutoimmune hepatitis
VascularBudd-Chiari syndrome, cardiac cirrhosis (right heart failure)
CryptogenicNo identifiable cause (~10-15% of cases)
The leading causes worldwide are chronic HBV, chronic HCV, MASLD, and alcohol-associated liver disease.

3. AETIOPATHOGENESIS OF CIRRHOSIS (General)

Regardless of cause, the shared pathogenetic pathway involves three key processes:

Step 1 - Repeated/Sustained Hepatocellular Injury

Any chronic stimulus (viral, toxic, metabolic, biliary) causes ongoing hepatocyte death via necrosis or apoptosis.

Step 2 - Stellate Cell Activation and Fibrogenesis

  • Damaged hepatocytes and Kupffer cells release TGF-β, TNF-α, IL-1, and platelet-derived growth factor (PDGF).
  • These cytokines activate hepatic stellate cells (Ito cells) in the space of Disse.
  • Activated stellate cells transform into myofibroblast-like cells and produce large amounts of type I and III collagen, fibronectin, and other extracellular matrix (ECM) components.
  • Result: progressive perisinusoidal fibrosis leading to "capillarization of sinusoids" (loss of fenestrations in the sinusoidal endothelium), which impairs exchange between blood and hepatocytes.

Step 3 - Regeneration and Nodule Formation

  • Surviving hepatocytes undergo regenerative hyperplasia, forming nodules without the normal lobular architecture.
  • These nodules are enclosed by fibrous septa that link portal tracts to central veins (bridging fibrosis), disrupting normal lobular architecture.

Step 4 - Vascular Distortion

  • Perivenular fibrosis and fibrous obliteration of terminal hepatic venules (phlebosclerosis)
  • Veno-occlusive lesions → sinusoidal hypertension → portal hypertension
  • Portosystemic shunting: blood bypasses functioning hepatocytes

4. AETIOPATHOGENESIS OF ALCOHOLIC CIRRHOSIS

4.1 Epidemiology

  • Alcohol accounts for 48% of cirrhosis worldwide, causing 1.16 million deaths annually
  • Only 10-20% of heavy drinkers develop cirrhosis - other cofactors are important
  • Threshold: 80 g/day of ethanol (80-proof liquor); cirrhosis typically takes 10-20 years to develop

4.2 Risk Factors for Progression

FactorMechanism
Amount/durationDose-dependent hepatotoxicity
Sex (female)Lower threshold; estrogen increases gut permeability to endotoxins → Kupffer cell TLR4 activation
GeneticsPNPLA3, MBOAT7, TM6SF2 polymorphisms; ALDH2 variants (common in Asians)
Obesity/MASLDSynergistic hepatotoxicity
Viral hepatitis (HBV/HCV)Additive liver injury
MalnutritionImpaired hepatic repair
SmokingIndependent risk factor
Gut microbiome dysbiosisIncreased intestinal permeability → endotoxaemia

4.3 Mechanisms of Alcohol-Induced Hepatocyte Injury

Ethanol Metabolism:
Ethanol → (ADH1) → Acetaldehyde → (ALDH) → Acetate
Ethanol → (CYP2E1, induced by chronic drinking) → Acetaldehyde + ROS
Specific injurious mechanisms:
  1. Altered redox state (NADH/NAD+ ratio):
    • Ethanol oxidation converts NAD+ to NADH
    • High NADH/NAD+ inhibits beta-oxidation of fatty acids and gluconeogenesis
    • Promotes fatty acid synthesis → hepatic steatosis
  2. Acetaldehyde toxicity:
    • Induces lipid peroxidation
    • Forms acetaldehyde-protein adducts → cytoskeletal and membrane disruption
    • May generate neoantigens triggering immune injury
  3. CYP2E1-induced oxidative stress:
    • Induction by chronic alcohol consumption increases reactive oxygen species (ROS)
    • ROS damage cellular proteins, membranes, and mitochondria
    • May promote hepatocyte apoptosis
  4. Impaired methionine metabolism:
    • Alcohol decreases hepatic glutathione levels → sensitisation to oxidative injury
    • Homocysteine production → endoplasmic reticulum (ER) stress
  5. Gut-derived endotoxaemia (LPS/PAMPs):
    • Alcohol increases gut permeability
    • Bacterial lipopolysaccharide (LPS) enters portal circulation
    • Activates Kupffer cells via TLR4/CD14
    • Triggers NLRP3 inflammasome, releasing IL-1β and caspase-1
    • Sustained Kupffer cell activation → chronic hepatic inflammation
  6. Mitochondrial dysfunction:
    • Impaired beta-oxidation → fat accumulation
    • Reduced oxidative phosphorylation → cellular energy deficiency
Alcohol-associated liver disease progression diagram showing stages from steatosis to cirrhosis
Progression of alcohol-associated liver disease: Steatosis → Steatohepatitis → Cirrhosis (Robbins, Cotran & Kumar)

5. MORPHOLOGY OF ALCOHOLIC CIRRHOSIS

5.1 Gross Morphology

Three overlapping, progressive stages:
Stage 1 - Hepatic Steatosis (Fatty Liver):
  • Liver enlarged (up to 4-6 kg), soft, yellow, greasy
  • Changes begin in centrilobular zone 3 and extend outward
  • Reversible with abstinence
Stage 2 - Alcoholic Steatohepatitis:
  • Liver may be enlarged or normal in size
  • Yellow-tan cut surface; may show irregular nodularity beginning
Stage 3 - Established Alcoholic Cirrhosis:
  • Liver is shrunken and firm in end-stage disease
  • Surface is diffusely nodular (bumpy texture); normal smooth capsule replaced by irregular surface with depressed scarring and bulging nodules
  • Micronodular pattern (Laennec's cirrhosis) initially: nodules <3 mm, uniform in size; with abstinence may evolve into a macronodular or mixed pattern
  • Cut surface shows alternating tan-yellow regenerative nodules separated by grey-white fibrous septa

5.2 Microscopic Morphology

Hepatic Steatosis:
  • Lipid droplets begin as small (microvesicular) then coalesce into large (macrovesicular) droplets
  • Macrovesicular steatosis predominates: fat displaces nucleus to periphery
  • Most prominent around central vein (zone 3)
Alcoholic Steatohepatitis (required for diagnosis of hepatitis):
FeatureDescription
Ballooned hepatocytesSwollen hepatocytes with cleared cytoplasm; cytoskeletal damage
Mallory-Denk bodies (Mallory hyaline)Intracytoplasmic eosinophilic inclusions = tangled skeins of ubiquitinated intermediate filaments (keratins 8 and 18)
Neutrophilic inflammationNeutrophils surround ballooned hepatocytes ("satellitosis"); more prominent than in MASLD
Lobular lymphocytic infiltratesAlso portal lymphocytic infiltrates
Necrosis/apoptosisUsually spotty; can be confluent in severe cases
Pericellular/perisinusoidal fibrosis"Chicken wire" fibrosis in zone 3; most characteristic early fibrotic pattern
Established Cirrhosis:
  • Fibrous septa interconnect portal tracts and central veins (bridging fibrosis)
  • Parenchyma replaced by regenerative nodules with disrupted lobular architecture
  • Perivenular fibrosis → phlebosclerosis (fibrous obliteration of terminal hepatic venules)
  • Loss of bile ductules in fibrous septa (ductular reaction)
  • Variable steatosis and residual inflammation
Microscopic image of alcoholic cirrhosis showing micronodular pattern with fibrous septa
Alcohol-associated cirrhosis: Micronodular pattern (smaller nodules at left) merging with macronodular areas (larger nodule at right). Dense blue fibrous bands separate regenerative nodules (Masson trichrome stain). - Robbins, Cotran & Kumar
Regression: With prolonged abstinence, fibrous septa become thin and incomplete. Most scars can regress (Fig. 14.6B from Robbins Basic Pathology), but complete regression of cirrhosis is rare.

6. CLINICAL FINDINGS

6.1 Compensated Cirrhosis (~40% asymptomatic)

  • Fatigue, weakness, anorexia, weight loss
  • Hepatomegaly (early); shrunken liver (late)
  • Mild elevation of liver enzymes

6.2 Specific Signs in Alcoholic Cirrhosis

Hepatic findings:
  • Hepatomegaly (tender in active hepatitis)
  • Jaundice (hyperbilirubinemia)
  • Dupuytren's contracture (palmar fibromatosis - classic in alcoholics)
Skin signs (hyperestrogenemia):
  • Spider angiomata (arterial spider naevi)
  • Palmar erythema
  • Gynecomastia, testicular atrophy, loss of libido (males)
  • Amenorrhoea (females)
  • Rhinophyma (bulbous red nose)
  • Jaundice and pruritus (from cholestasis; bile salt accumulation)
Signs of portal hypertension:
  • Ascites
  • Caput medusae (dilated periumbilical veins)
  • Splenomegaly
  • Haemorrhoids
Neurological:
  • Hepatic encephalopathy (asterixis/flapping tremor, confusion, coma)
  • Peripheral neuropathy (from vitamin B1/B12 deficiency)
Other:
  • Malnutrition and sarcopenia
  • Ecchymoses/bleeding tendency (coagulopathy from decreased clotting factor synthesis)
  • Oedema (hypoalbuminaemia)
  • Parotid enlargement

6.3 Laboratory Findings

TestFinding
AST/ALT ratio>2:1 (rarely >300 IU/L) - characteristic of ALD
AST, ALTElevated (AST > ALT)
GGTElevated (sensitive marker)
BilirubinElevated
AlbuminDecreased
PT/INRProlonged
PlateletsDecreased (hypersplenism)
CBCAnaemia (multifactorial)
Serum bilirubin >3 mg/dLSuggests hepatitis component

7. COMPLICATIONS

Clinical consequences of portal hypertension in cirrhosis
Major clinical consequences of portal hypertension in cirrhosis - Robbins Basic Pathology

A. Portal Hypertension

  • Mechanism: increased sinusoidal resistance (fibrosis + stellate cell contraction) + increased portal blood flow (splanchnic vasodilation)
  • Leads to all downstream complications

B. Oesophageal and Gastric Varices

  • Develop in ~40% of patients with advanced cirrhosis
  • Portosystemic collaterals at oesophago-gastric junction
  • Variceal bleeding: massive haematemesis; frequently fatal especially with coagulopathy

C. Ascites

  • ~85% of ascites cases are due to portal hypertension from cirrhosis
  • Transudate: protein <3 g/dL; serum-to-ascites albumin gradient (SAAG) ≥1.1 g/dL
  • Mechanism: portal hypertension + hypoalbuminaemia + renal sodium/water retention (RAAS activation)
  • Risk: Spontaneous Bacterial Peritonitis (SBP)

D. Hepatic Encephalopathy

  • Accumulation of neurotoxins (ammonia, manganese, false neurotransmitters) due to portosystemic shunting and reduced hepatocyte function
  • Clinical stages: from subtle personality changes → confusion → stupor → coma
  • Precipitants: GI bleeding, infection, sedatives, hypokalemia, constipation

E. Hepatorenal Syndrome (HRS)

  • Functional renal failure without intrinsic renal disease
  • Mechanism: liver failure → vasodilator production (NO) → splanchnic vasodilation → decreased renal perfusion → renal vasoconstriction via renin-angiotensin and renal sympathetic activation
  • Reversible if liver function restored (e.g., liver transplantation)

F. Splenomegaly and Hypersplenism

  • Congestive splenomegaly from portal hypertension
  • Spleen may reach 1000 g
  • Hypersplenism → thrombocytopenia, anaemia, leukopenia (pancytopenia)

G. Coagulopathy

  • Decreased synthesis of clotting factors (I, II, V, VII, IX, X) by failing hepatocytes
  • Risk of spontaneous bleeding

H. Hepatocellular Carcinoma (HCC)

  • Annual risk: 1-6% in alcoholic cirrhosis
  • Cirrhosis of any cause is the single most important risk factor for HCC
  • Most chronic liver diseases predispose to HCC

I. Portopulmonary Hypertension

  • Pulmonary vasoconstriction due to vasoactive substances bypassing liver

J. Acute-on-Chronic Liver Failure

  • Sudden decompensation triggered by: infection, GI bleed, superimposed acute hepatitis, drugs

8. PROGNOSIS

  • 5-year survival in abstainers (free of jaundice, ascites, hematemesis): ~90%
  • 5-year survival with continued drinking: 50-60%
  • Common causes of death:
    1. Hepatic coma (liver failure)
    2. Massive GI haemorrhage (variceal bleeding)
    3. Intercurrent infection (sepsis, SBP)
    4. Hepatorenal syndrome
    5. Hepatocellular carcinoma
Child-Pugh score (bilirubin, albumin, PT, ascites, encephalopathy) and MELD score (bilirubin, creatinine, INR) are used to assess severity and guide transplantation eligibility.

Sources: Robbins, Cotran & Kumar - Pathologic Basis of Disease (9780443264528); Robbins & Kumar - Basic Pathology (9780323790185); Harrison's Principles of Internal Medicine 22E (9781265977061)

Discuss the pathology of regenerative and neoplastic helatocellular nodules

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Loading Image
Reading File
Reading File
Finding Sources
Loading Image
Loading Image
I now have comprehensive content from the textbooks. Let me compile the full answer.

Pathology of Regenerative and Neoplastic Hepatocellular Nodules

Hepatocellular nodules form a spectrum from benign regenerative responses through premalignant dysplasia to frank carcinoma. Understanding this spectrum is fundamental to liver pathology.

OVERVIEW: THE NODULAR SPECTRUM

Cirrhotic/Regenerative Nodule
         ↓
    Large Cell Change
    Small Cell Change
         ↓
  Low-Grade Dysplastic Nodule
         ↓
  High-Grade Dysplastic Nodule (+ "nodule-in-nodule")
         ↓
  Early / Well-differentiated HCC
         ↓
  Overt / Advanced HCC
Also considered separately as non-cirrhotic regenerative lesions:
  • Focal Nodular Hyperplasia (FNH)
  • Hepatocellular Adenoma

I. REGENERATIVE NODULES

A. Cirrhotic (Regenerative) Nodules

These are the basic structural units of cirrhosis and are not premalignant per se.
Pathogenesis: Following repeated cycles of hepatocyte injury and death, surviving hepatocytes undergo compensatory regenerative hyperplasia, forming clonal clusters surrounded by fibrous septa.
Morphology:
  • Microscopically: nodules composed of hepatocytes with preserved lobular architecture (though simplified); cells are normal in size and cytology
  • Surrounded by fibrous bands (portal-to-portal or portal-to-central bridging fibrosis)
  • No cytologic atypia
  • Micronodular (<3 mm, seen in alcoholic/metabolic disease) or macronodular (>3 mm, seen in post-viral disease)

B. Large Cell Change (Large Cell Dysplasia)

An early at-risk alteration seen in chronic liver disease, particularly viral hepatitis.
Morphology:
  • Hepatocytes that are enlarged with large, often atypical nuclei (nuclear enlargement proportional to cytoplasmic enlargement)
  • Scattered throughout the lobule; do not form discrete nodules
  • Not a truly dysplastic lesion in a strict sense - may represent a senescent, stress-induced change
  • Associated with HCV infection and cirrhosis
Premalignant changes in hepatocytes: Large cell change (A) and Small cell change (B)
(A) Large cell change: enlarged hepatocytes with large atypical nuclei. (B) Small cell change: high nuclear-to-cytoplasmic ratio with thickened cell plates. - Robbins, Cotran & Kumar

C. Small Cell Change

Considered to carry a higher premalignant risk than large cell change.
Morphology:
  • Hepatocytes are smaller than normal with a high nuclear-to-cytoplasmic (N:C) ratio
  • Cells grow in thickened plates (2-3 cell plates thick vs normal 1-2)
  • Clusters may form and are clonal
  • Most closely associated with early HCC and high-grade dysplastic nodules

D. Focal Nodular Hyperplasia (FNH)

A non-neoplastic, regenerative mass lesion occurring in otherwise normal liver. It is the second most common benign hepatic lesion after haemangioma.
Pathogenesis: Thought to arise in response to a pre-existing arterial malformation/vascular anomaly causing local hepatocyte hyperplasia. Not associated with oral contraceptive use (unlike adenoma).
Demographics: Most common in young to middle-aged women; usually asymptomatic, discovered incidentally.
Gross Morphology:
  • Well-demarcated but poorly encapsulated nodule, may be several centimeters in diameter
  • Central stellate (star-shaped) fibrous scar - pathognomonic feature - from which fibrous septa radiate to periphery
  • Normal background liver
Microscopic Morphology:
  • Central scar contains large anomalous (thick-walled) arteries and ductular reactions along the fibrous septa
  • Hepatocytes appear normal histologically
  • No encapsulation; no portal tracts in nodular parenchyma
  • No cytologic atypia, no malignant potential
Clinical significance: Benign; rarely causes symptoms; does not require resection unless symptomatic.

II. HEPATOCELLULAR ADENOMA (Benign Neoplasm)

A true benign neoplasm of hepatocytes arising in a non-cirrhotic liver.
Associations:
  • Reproductive-age women (historically linked to oral contraceptive pills, now more linked to obesity and metabolic syndrome)
  • Anabolic steroid use in men
  • Glycogen storage disease
Molecular subtypes:
SubtypeMutationFeatures
HNF1α-inactivatedHNF1α lossMarked steatosis; LFABP absent on IHC; low malignant risk
β-catenin-activatedCTNNB1 gain-of-functionHigh risk of malignant transformation to HCC; nuclear β-catenin on IHC
InflammatoryIL6ST/STAT3 pathwayMarked sinusoidal dilation; serum amyloid A/CRP positive on IHC
UnclassifiedUnknown~10% of cases
Gross Morphology:
  • Usually solitary, well-demarcated mass; no fibrous capsule (or thin capsule)
  • May have areas of haemorrhage or necrosis (particularly when large, >5 cm)
  • No central scar (distinguishes from FNH)
  • Cut surface: pale-tan to yellow
Microscopic Morphology:
  • Sheets and cords of hepatocytes resembling normal hepatocytes
  • Arterial vascular supply (unpaired arteries without portal tracts) - key diagnostic feature
  • No portal tracts within the tumour
  • No bile ducts within the tumour
  • Variable degree of cytologic atypia depending on subtype; β-catenin-activated type shows most atypia
Complications:
  • Haemorrhage and rupture (especially >5 cm) → life-threatening intra-abdominal bleeding
  • Malignant transformation to HCC (especially β-catenin-activated subtype)
Management: Resection recommended for male patients (regardless of size), β-catenin-activated tumours, and tumours ≥5 cm.

III. DYSPLASTIC NODULES (Premalignant)

Dysplastic nodules arise in cirrhotic liver and represent clonal proliferations with molecular alterations overlapping with HCC. They are recognised by the International Consensus Group for Hepatocellular Neoplasia.

A. Low-Grade Dysplastic Nodule (LGDN)

  • Slightly larger than surrounding cirrhotic nodules
  • Mild cytologic atypia: slightly increased N:C ratio, mild nuclear irregularity
  • Architecture largely preserved; no increased cell density
  • Clonal, but few molecular aberrations
  • No increased arterialization
  • Low but not zero risk of progression

B. High-Grade Dysplastic Nodule (HGDN)

  • Distinctly larger than surrounding cirrhotic nodules
  • Significant cytologic atypia: prominent nuclear irregularity, increased N:C ratio, mitotic figures
  • Increased cell density; thickened plates
  • Small cell change prominent
  • Clonal aberrations associated with overt HCC (TERT promoter mutations, etc.)
  • Increased unpaired arteries (arterial neovascularisation begins)
  • "Nodule-in-nodule" appearance: small foci of overt HCC visible within the dysplastic nodule
Cirrhosis with a large dysplastic nodule showing nodule-in-nodule growth (early HCC)
Hepatitis C cirrhosis with a distinctively large dysplastic nodule (arrows). Nodule-in-nodule growth indicates early HCC (A, gross; B, histology). - Robbins, Cotran & Kumar

IV. HEPATOCELLULAR CARCINOMA (HCC)

The most common primary malignant liver tumour; represents the neoplastic end of the hepatocellular nodule spectrum.

Epidemiology

  • ~5-5.4% of all cancers worldwide
  • 85% of cases occur in Asia (SE China, Korea, Taiwan) and sub-Saharan Africa (endemic HBV)
  • Male predominance: 3:1 (low-incidence areas) to 8:1 (high-incidence areas)
  • Rising in Western countries due to HCV and MASLD

Risk Factors / Aetiology

FactorMechanism
HBV (most important globally)Integration into host genome disrupts tumour suppressors; HBx protein inhibits p53
HCVChronic inflammation + cirrhosis drives mutagenesis
Aflatoxin B1 (Aspergillus)Mutagen: G:C→T:A transversion in codon 249 of TP53; synergises with HBV
AlcoholVia cirrhosis; synergises with HBV, HCV
MASLD/NAFLDVia metabolic syndrome and cirrhosis
Hereditary haemochromatosisIron-induced oxidative DNA damage
α1-antitrypsin deficiencyProtein accumulation drives hepatocyte injury
Wilson diseaseCopper-induced oxidative damage
Cirrhosis (any cause)Chronic regeneration increases mutation acquisition

Pathogenesis / Molecular Biology

  • Chronic liver injury → hepatocyte regeneration → acquisition of driver mutations
  • Viruses and toxins are not directly oncogenic; rather, inflammation drives proliferation and mutagenesis
  • Key driver mutations in HCC:
    • TERT promoter mutations (50-60% of tumours) - upregulate telomerase, prevent replicative senescence
    • β-catenin (CTNNB1) activating mutations (~40%) - activate Wnt signalling, promote proliferation
    • TP53 inactivating mutations (up to 60%) - loss of cell cycle arrest/apoptosis
    • CDKN2A (p16) loss, PI3K/AKT/mTOR pathway activation
  • In noncirrhotic liver, HCC can arise from malignant transformation of hepatocellular adenoma (especially β-catenin-activated)
  • Aflatoxin causes a characteristic TP53 "hotspot" mutation at codon 249 (Arg→Ser)

Gross Morphology

Three patterns:
  1. Unifocal (usually large) mass - most common; may replace an entire lobe
  2. Multifocal, widely distributed nodules of variable size
  3. Diffusely infiltrative - permeates widely through liver, sometimes involving entire liver; may be mistaken for cirrhosis grossly
Additional features:
  • Pale yellow (fatty change) or green (bile production) cut surface
  • Tumours >2 cm more likely to show vascular invasion and intrahepatic metastases
  • Portal vein invasion: snake-like tumour thrombus extending into portal vein → portal hypertension
  • Extension into inferior vena cava and even right ventricle in advanced cases
  • Satellite nodules around primary mass (intrahepatic metastases)
HCC: Unifocal mass replacing right hepatic lobe (A) and histology showing pseudoacinar pattern (B)
HCC: (A) Unifocal neoplasm replacing most of the right lobe. (B) Distorted trabeculae and pseudoacinar spaces (malformed bile canaliculi). - Robbins, Cotran & Kumar

Microscopic Morphology

Histological grades:
GradeFeatures
Well-differentiatedCells closely resemble normal hepatocytes; grow as thick trabeculae (2-3 cell plates) or pseudoglandular/acinar patterns; bile plugs in pseudoacini; mild nuclear atypia
Moderately differentiatedRecognisable hepatocytes; more nuclear atypia; mitoses; vascular invasion may be seen
Poorly differentiated / AnaplasticMarked nuclear pleomorphism; giant cells; frequent mitoses; may lose hepatocellular differentiation; spindle cell areas
Histological growth patterns:
  • Trabecular (sinusoidal) - most common; thickened liver cell plates separated by sinusoids lined by flattened endothelial cells
  • Pseudoglandular (acinar) - dilated bile canaliculi form pseudoacini; bile plugs present
  • Solid/compact - sheets of cells with minimal sinusoidal stroma
  • Scirrhous - prominent fibrous stroma (must be distinguished from cholangiocarcinoma)
Immunohistochemistry:
  • HepPar-1 (hepatocyte paraffin antigen 1) - most specific hepatocellular marker
  • Glypican-3 (GPC3) - sensitive for HCC, especially well-differentiated
  • AFP - in tumour cells (correlates with serum levels)
  • Arginase-1 - highly sensitive and specific
  • Polyclonal CEA - canalicular/bile canalicular pattern (pCEA)

The Fibrolamellar Variant

A distinctive subtype with entirely different clinicopathological features:
  • Affects adolescents and young adults (median age 25 years)
  • No preexisting liver disease or cirrhosis
  • No elevated AFP
  • Better prognosis than conventional HCC (up to 40% survive 10 years)
  • Molecular hallmark: DNAJB1::PRKACA fusion gene → excessive protein kinase A activity
Morphology (characteristic triad):
  1. Large polygonal cells with abundant granular eosinophilic cytoplasm (due to abundant mitochondria - oncocytic change)
  2. Vesicular nuclei with a single prominent nucleolus
  3. Parallel lamellae of dense collagen (lamellar fibrosis) separating tumour cells
Gross: Large, well-demarcated nodule, often with a central scar (may mimic FNH)
Fibrolamellar HCC: characteristic gross appearance (A) and lamellar collagen pattern on histology (B)
Fibrolamellar carcinoma: (A) Well-demarcated nodule. (B) Large eosinophilic cells with prominent nucleoli separated by lamellated collagen bands. - Robbins, Cotran & Kumar

V. COMPARATIVE SUMMARY TABLE

FeatureRegenerative Nodule (Cirrhosis)FNHHCALow-Grade DNHigh-Grade DNHCC
Background liverCirrhoticNormalNormal/non-cirrhoticCirrhoticCirrhoticCirrhotic (85%)
Fibrous scarSurrounding septaCentral stellate scarNoNoNoNo
Portal tractsPresentAbsent in noduleAbsentReducedAbsentAbsent
Bile ductsPresentPresent (ductular rx)AbsentReducedAbsentAbsent
ArteriesNormal (paired)Thick-walled centralUnpaired arteriesSlightly increasedIncreased unpairedMarkedly increased
Cytologic atypiaNoneNoneMinimal-moderateMildModerate-markedMarked
Cell plates1-2 cells thick1-21-21-22-3>3 (trabecular)
AFPNormalNormalNormalNormalNormal/slightly elevatedElevated (50-60%)
Malignant potentialNoneNoneLow-moderate (β-cat type)LowHighN/A (is malignant)

VI. CLINICAL FEATURES OF HCC

  • Symptoms: Upper abdominal pain, malaise, fatigue, weight loss, awareness of abdominal mass
  • Jaundice and ascites: Due to underlying cirrhosis or portal vein invasion
  • Haemoperitoneum: From spontaneous rupture (especially in sub-Saharan Africa)
  • Paraneoplastic syndromes: Hypoglycaemia (insulin-like activity), erythrocytosis (ectopic EPO), hypercalcaemia, hypercholesterolaemia

Laboratory Findings

  • Serum AFP elevated in ~50% of advanced HCC; not sensitive for early disease; not elevated in fibrolamellar variant
  • AST, ALT, ALP: May be elevated or normal (HCC can arise in relatively preserved liver)
  • LDH: Often elevated

Imaging Hallmark

  • Contrast-enhanced CT/MRI: Arterial phase enhancement followed by rapid venous washout - pathognomonic of HCC (reflects high arterialization)
  • LI-RADS scoring system used for standardised radiological reporting

Prognosis and Treatment

Stage/Treatment5-year Survival
Confined to liver (small, resectable)~30-40%
Extrahepatic spread~5%
Fibrolamellar variantUp to 40% at 10 years
Treatment options:
  • Surgical resection (curative; requires adequate liver reserve)
  • Liver transplantation (Milan criteria: single tumour ≤5 cm or ≤3 tumours each ≤3 cm; no vascular invasion)
  • Radiofrequency ablation / microwave ablation / ethanol injection (unresectable small tumours)
  • Transarterial chemoembolisation (TACE) - exploits HCC arterialization
  • Sorafenib (kinase inhibitor) - palliative; prolongs survival in advanced disease
  • Immune checkpoint inhibitors (atezolizumab + bevacizumab) - current first-line systemic therapy
Causes of death:
  1. Cachexia
  2. GI/variceal haemorrhage
  3. Liver failure / hepatic coma
  4. Tumour rupture with haemoperitoneum (less common)

Sources: Robbins, Cotran & Kumar - Pathologic Basis of Disease (9780443264528, pp. 807-808); Robbins & Kumar Basic Pathology (9780323790185, pp. 625-630)

Please give pff

Reading File
Running Command

ls /home/daytona/workspace/ 2>/dev/null && echo "---" && ls /home/daytona/workspace/attachments/ 2>/dev/null || echo "No attachments folder"

Running Command

mkdir -p /home/daytona/workspace/liver-pathology && echo "done"

Writing File

~/liver-pathology/generate_pdf.py

from reportlab.lib.pagesizes import A4
from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle
from reportlab.lib.units import cm
from reportlab.lib import colors
from reportlab.platypus import (
    SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle,
    HRFlowable, KeepTogether, ListFlowable, ListItem, PageBreak
)
from reportlab.lib.enums import TA_LEFT, TA_CENTER, TA_JUSTIFY
from reportlab.platypus import Flowable

OUTPUT = "/home/daytona/workspace/liver-pathology/Hepatocellular_Nodules_Pathology.pdf"

doc = SimpleDocTemplate(
    OUTPUT,
    pagesize=A4,
    rightMargin=2*cm,
    leftMargin=2*cm,
    topMargin=2.2*cm,
    bottomMargin=2*cm,
)

W = A4[0] - 4*cm  # usable width

styles = getSampleStyleSheet()

# Custom styles
TITLE = ParagraphStyle('Title', parent=styles['Normal'],
    fontName='Helvetica-Bold', fontSize=16, textColor=colors.HexColor('#1a3557'),
    spaceAfter=6, alignment=TA_CENTER, leading=20)

SUBTITLE = ParagraphStyle('Subtitle', parent=styles['Normal'],
    fontName='Helvetica', fontSize=10, textColor=colors.HexColor('#444444'),
    spaceAfter=14, alignment=TA_CENTER)

H1 = ParagraphStyle('H1', parent=styles['Normal'],
    fontName='Helvetica-Bold', fontSize=13, textColor=colors.HexColor('#1a3557'),
    spaceBefore=14, spaceAfter=4, borderPad=2,
    backColor=colors.HexColor('#e8f0f7'), leading=16,
    leftIndent=0)

H2 = ParagraphStyle('H2', parent=styles['Normal'],
    fontName='Helvetica-Bold', fontSize=11, textColor=colors.HexColor('#2e5c8a'),
    spaceBefore=10, spaceAfter=3, leading=14)

H3 = ParagraphStyle('H3', parent=styles['Normal'],
    fontName='Helvetica-BoldOblique', fontSize=10, textColor=colors.HexColor('#3a7bd5'),
    spaceBefore=7, spaceAfter=2, leading=13)

BODY = ParagraphStyle('Body', parent=styles['Normal'],
    fontName='Helvetica', fontSize=9.5, textColor=colors.HexColor('#222222'),
    spaceAfter=5, leading=14, alignment=TA_JUSTIFY)

BULLET = ParagraphStyle('Bullet', parent=styles['Normal'],
    fontName='Helvetica', fontSize=9.5, textColor=colors.HexColor('#222222'),
    spaceAfter=3, leading=13, leftIndent=14, bulletIndent=4)

CODE = ParagraphStyle('Code', parent=styles['Normal'],
    fontName='Courier', fontSize=9, textColor=colors.HexColor('#333333'),
    backColor=colors.HexColor('#f0f4f8'), spaceAfter=6, leading=12,
    leftIndent=10, rightIndent=10)

SOURCE = ParagraphStyle('Source', parent=styles['Normal'],
    fontName='Helvetica-Oblique', fontSize=8, textColor=colors.HexColor('#666666'),
    spaceAfter=14, alignment=TA_CENTER)

NOTE = ParagraphStyle('Note', parent=styles['Normal'],
    fontName='Helvetica-Oblique', fontSize=8.5, textColor=colors.HexColor('#555555'),
    spaceAfter=4, leading=12, leftIndent=8, borderPad=4,
    backColor=colors.HexColor('#fffbe6'))

def hr():
    return HRFlowable(width="100%", thickness=0.5, color=colors.HexColor('#c8d8e8'), spaceAfter=4, spaceBefore=2)

def h1(text):
    return Paragraph(f"&nbsp; {text}", H1)

def h2(text):
    return Paragraph(text, H2)

def h3(text):
    return Paragraph(text, H3)

def body(text):
    return Paragraph(text, BODY)

def bullet(text):
    return Paragraph(f"• {text}", BULLET)

def sp(h=6):
    return Spacer(1, h)

def make_table(headers, rows, col_widths=None):
    data = [headers] + rows
    if col_widths is None:
        n = len(headers)
        col_widths = [W/n] * n
    t = Table(data, colWidths=col_widths, repeatRows=1)
    t.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,0), colors.HexColor('#1a3557')),
        ('TEXTCOLOR', (0,0), (-1,0), colors.white),
        ('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
        ('FONTSIZE', (0,0), (-1,0), 8.5),
        ('FONTNAME', (0,1), (-1,-1), 'Helvetica'),
        ('FONTSIZE', (0,1), (-1,-1), 8.5),
        ('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.white, colors.HexColor('#f0f5fb')]),
        ('GRID', (0,0), (-1,-1), 0.4, colors.HexColor('#c0cfe0')),
        ('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
        ('TOPPADDING', (0,0), (-1,-1), 4),
        ('BOTTOMPADDING', (0,0), (-1,-1), 4),
        ('LEFTPADDING', (0,0), (-1,-1), 6),
        ('RIGHTPADDING', (0,0), (-1,-1), 6),
        ('WORDWRAP', (0,0), (-1,-1), True),
    ]))
    return t

story = []

# ── COVER ──────────────────────────────────────────────────────────────────
story.append(sp(30))
story.append(Paragraph("PATHOLOGY OF LIVER NODULES", TITLE))
story.append(Paragraph("Regenerative &amp; Neoplastic Hepatocellular Nodules", ParagraphStyle('ST2',
    parent=TITLE, fontSize=12, textColor=colors.HexColor('#2e5c8a'), spaceBefore=4, spaceAfter=4)))
story.append(sp(6))
story.append(hr())
story.append(Paragraph("Based on Robbins, Cotran &amp; Kumar — Pathologic Basis of Disease | Robbins &amp; Kumar Basic Pathology | Harrison's Principles of Internal Medicine 22E", SOURCE))
story.append(sp(20))

# ── SPECTRUM OVERVIEW ──────────────────────────────────────────────────────
story.append(h1("THE NODULAR SPECTRUM"))
story.append(body(
    "Hepatocellular nodules form a continuous spectrum from benign regenerative responses through premalignant "
    "dysplasia to frank hepatocellular carcinoma. This progression reflects accumulating molecular damage during chronic liver injury."))
story.append(sp(6))

spectrum_data = [
    ["Stage", "Type", "Setting", "Malignant Risk"],
    ["1", "Regenerative / Cirrhotic Nodule", "Cirrhosis", "None"],
    ["2", "Large Cell Change", "Chronic hepatitis / cirrhosis", "Low"],
    ["3", "Small Cell Change", "Cirrhosis", "Moderate"],
    ["4", "Low-Grade Dysplastic Nodule (LGDN)", "Cirrhosis", "Low–Moderate"],
    ["5", "High-Grade Dysplastic Nodule (HGDN)", "Cirrhosis", "High"],
    ["6", "Early / Well-differentiated HCC", "Cirrhosis", "Malignant"],
    ["7", "Overt / Advanced HCC", "Cirrhosis (85%) / non-cirrhotic (15%)", "Malignant"],
]
story.append(make_table(spectrum_data[0], spectrum_data[1:],
    col_widths=[1.0*cm, 5.8*cm, 5.0*cm, 3.0*cm]))
story.append(sp(4))
story.append(Paragraph("Non-cirrhotic nodular lesions: Focal Nodular Hyperplasia (FNH) and Hepatocellular Adenoma are discussed separately.", NOTE))

# ── I. REGENERATIVE NODULES ────────────────────────────────────────────────
story.append(h1("I. REGENERATIVE NODULES"))

story.append(h2("A. Cirrhotic (Regenerative) Nodules"))
story.append(body(
    "These are the basic structural units of cirrhosis — clonal clusters of surviving hepatocytes enclosed by fibrous septa. "
    "They are <b>not premalignant</b> per se. Following repeated cycles of hepatocyte injury and death, surviving cells "
    "undergo compensatory regenerative hyperplasia."))
story.append(bullet("<b>Gross:</b> Micronodular (&lt;3 mm, uniform — alcoholic/metabolic) or macronodular (&gt;3 mm, variable — post-viral)"))
story.append(bullet("<b>Micro:</b> Normal hepatocyte cytology; preserved (though simplified) lobular architecture; no cytologic atypia"))
story.append(bullet("Surrounded by fibrous bands (portal-to-portal or portal-to-central bridging fibrosis)"))
story.append(sp(4))

story.append(h2("B. Large Cell Change (Large Cell Dysplasia)"))
story.append(body(
    "An early <b>at-risk alteration</b> seen in chronic liver disease, particularly viral hepatitis (HCV). "
    "May represent a senescent, stress-induced change rather than true dysplasia."))
story.append(bullet("<b>Micro:</b> Hepatocytes enlarged; large, often atypical nuclei — nuclear enlargement proportional to cytoplasmic enlargement"))
story.append(bullet("Scattered throughout lobule; do not form discrete nodules"))
story.append(bullet("Associated with HCV infection and cirrhosis"))
story.append(sp(4))

story.append(h2("C. Small Cell Change"))
story.append(body("Considered to carry a <b>higher premalignant risk</b> than large cell change; most closely associated with early HCC."))
story.append(bullet("<b>Micro:</b> Hepatocytes smaller than normal with a <b>high nuclear-to-cytoplasmic (N:C) ratio</b>"))
story.append(bullet("Cells grow in thickened plates (2–3 cell layers vs normal 1–2)"))
story.append(bullet("Clusters are clonal; prominent in high-grade dysplastic nodules"))

# ── II. FNH ───────────────────────────────────────────────────────────────
story.append(h1("II. FOCAL NODULAR HYPERPLASIA (FNH)"))
story.append(body(
    "A <b>non-neoplastic, regenerative</b> mass lesion in an otherwise normal liver. Second most common benign hepatic lesion "
    "after haemangioma. Thought to arise in response to a pre-existing arterial malformation causing local hepatocyte hyperplasia. "
    "<b>No malignant potential.</b>"))
story.append(sp(3))

fnh_data = [
    ["Feature", "Detail"],
    ["Demographics", "Young–middle-aged women; usually asymptomatic, found incidentally"],
    ["Gross", "Well-demarcated, poorly encapsulated nodule; central stellate (star-shaped) fibrous scar — PATHOGNOMONIC"],
    ["Central scar", "Contains large anomalous (thick-walled) arteries and ductular reactions; fibrous septa radiate to periphery"],
    ["Microscopy", "Normal hepatocyte histology; no cytologic atypia; no portal tracts within nodule"],
    ["Distinguishes from HCA", "Central scar present; bile ducts present (ductular reaction); not associated with OCP"],
    ["Malignant risk", "None — management is conservative unless symptomatic"],
]
story.append(make_table(fnh_data[0], fnh_data[1:], col_widths=[4.5*cm, 10.3*cm]))

# ── III. HEPATOCELLULAR ADENOMA ───────────────────────────────────────────
story.append(h1("III. HEPATOCELLULAR ADENOMA (Benign Neoplasm)"))
story.append(body(
    "A <b>true benign neoplasm</b> of hepatocytes arising in a non-cirrhotic liver. "
    "Historically linked to oral contraceptive pills (OCP); now more associated with obesity and metabolic syndrome."))
story.append(sp(4))

story.append(h2("Molecular Subtypes"))
subtype_data = [
    ["Subtype", "Mutation", "Key Features", "Malignant Risk"],
    ["HNF1α-inactivated\n(~35%)", "HNF1α loss-of-function", "Marked steatosis; LFABP absent on IHC", "Low"],
    ["β-catenin-activated\n(~10%)", "CTNNB1 gain-of-function", "Nuclear β-catenin on IHC; cytologic atypia", "HIGH — resect"],
    ["Inflammatory\n(~40%)", "IL6ST/STAT3 pathway", "Sinusoidal dilation; serum amyloid A/CRP+ on IHC", "Low–Moderate"],
    ["Unclassified\n(~10%)", "Unknown", "No specific markers", "Uncertain"],
]
story.append(make_table(subtype_data[0], subtype_data[1:], col_widths=[3.5*cm, 4.5*cm, 5.0*cm, 1.8*cm]))
story.append(sp(6))

story.append(h2("Morphology"))
story.append(bullet("<b>Gross:</b> Usually solitary, well-demarcated; no central scar (distinguishes from FNH); may show areas of haemorrhage/necrosis especially when &gt;5 cm"))
story.append(bullet("<b>Micro:</b> Sheets/cords of normal-appearing hepatocytes; <b>unpaired arteries without portal tracts</b>; no bile ducts within tumour"))
story.append(bullet("Variable cytologic atypia — most marked in β-catenin-activated subtype"))
story.append(sp(4))

story.append(h2("Complications"))
story.append(bullet("<b>Haemorrhage and rupture</b> (especially &gt;5 cm) → life-threatening intra-abdominal bleeding"))
story.append(bullet("<b>Malignant transformation to HCC</b> (especially β-catenin-activated subtype)"))
story.append(bullet("<b>Management:</b> Resection recommended for male patients (regardless of size), β-catenin-activated tumours, and tumours ≥5 cm"))

# ── IV. DYSPLASTIC NODULES ────────────────────────────────────────────────
story.append(h1("IV. DYSPLASTIC NODULES (Premalignant)"))
story.append(body(
    "Dysplastic nodules arise in <b>cirrhotic liver</b> and represent clonal proliferations with molecular alterations "
    "overlapping with HCC. They are recognised by the International Consensus Group for Hepatocellular Neoplasia. "
    "They differ from adjacent cirrhotic nodules in size, colour, and vascularisation."))
story.append(sp(4))

dn_compare = [
    ["Feature", "Low-Grade DN (LGDN)", "High-Grade DN (HGDN)"],
    ["Size", "Slightly larger than cirrhotic nodules", "Distinctly larger than cirrhotic nodules"],
    ["Cytologic atypia", "Mild — slight ↑ N:C ratio, mild nuclear irregularity", "Significant — prominent nuclear irregularity, mitoses"],
    ["Cell density", "Near-normal", "Increased; thickened plates (2–3 cells)"],
    ["Small cell change", "Minimal", "Prominent"],
    ["Arterialization", "No increase", "Increased unpaired arteries"],
    ["Molecular changes", "Few clonal aberrations", "TERT promoter mutations; overlapping with HCC"],
    ["'Nodule-in-nodule'", "Absent", "Present — small HCC foci visible within nodule"],
    ["Malignant potential", "Low–Moderate", "HIGH"],
]
story.append(make_table(dn_compare[0], dn_compare[1:], col_widths=[3.8*cm, 6.5*cm, 4.5*cm]))
story.append(sp(4))
story.append(body(
    "<b>Nodule-in-nodule appearance:</b> A focus of well-differentiated HCC developing within a high-grade dysplastic nodule, "
    "visible as a distinct subnodule that differs in colour, texture, or histologic grade from the surrounding dysplastic tissue. "
    "This is the morphologic hallmark of early hepatocarcinogenesis."))

# ── V. HEPATOCELLULAR CARCINOMA ───────────────────────────────────────────
story.append(PageBreak())
story.append(h1("V. HEPATOCELLULAR CARCINOMA (HCC)"))
story.append(body(
    "The most common primary malignant liver tumour; the neoplastic end of the hepatocellular nodule spectrum. "
    "Accounts for ~5–5.4% of all cancers worldwide."))

story.append(h2("Epidemiology"))
story.append(bullet(">85% of cases occur in Asia (SE China, Korea, Taiwan) and sub-Saharan Africa (endemic HBV)"))
story.append(bullet("Male predominance: 3:1 (low-incidence) to 8:1 (high-incidence areas)"))
story.append(bullet("Rising incidence in Western countries due to HCV and MASLD/metabolic syndrome"))
story.append(bullet("15–20% arise in non-cirrhotic livers (especially in HBV-endemic regions and aflatoxin-exposed populations)"))
story.append(sp(4))

story.append(h2("Risk Factors and Aetiology"))
rf_data = [
    ["Risk Factor", "Mechanism"],
    ["HBV (most important globally)", "Viral integration disrupts tumour suppressors; HBx protein inhibits p53; vertical transmission in infancy"],
    ["HCV", "Chronic inflammation + cirrhosis drives mutagenesis"],
    ["Aflatoxin B1 (Aspergillus spp.)", "G:C→T:A transversion at TP53 codon 249; synergises with HBV dramatically"],
    ["Alcohol", "Via cirrhosis; synergises with HBV, HCV; annual HCC risk 1–6% in alcoholic cirrhosis"],
    ["MASLD/NAFLD", "Via metabolic syndrome and cirrhosis; increasing importance in Western countries"],
    ["Hereditary haemochromatosis", "Iron-induced oxidative DNA damage"],
    ["α1-antitrypsin deficiency", "Protein accumulation drives chronic hepatocyte injury"],
    ["Wilson disease", "Copper-induced oxidative damage; somewhat lower risk"],
    ["Cirrhosis (any cause)", "Chronic regeneration increases rate of driver mutation acquisition"],
]
story.append(make_table(rf_data[0], rf_data[1:], col_widths=[5.0*cm, 9.8*cm]))
story.append(sp(6))

story.append(h2("Pathogenesis / Molecular Biology"))
story.append(body(
    "Viruses and toxins are not directly oncogenic. Rather, <b>chronic inflammation, cytokines, and growth factors "
    "promote hepatocyte proliferation and predispose to acquisition of driver mutations</b>. "
    "Progression to cirrhosis and liver carcinogenesis run in parallel."))
story.append(sp(3))

mol_data = [
    ["Driver Mutation/Event", "Frequency", "Effect"],
    ["TERT promoter mutations", "50–60%", "Upregulate telomerase → prevent replicative senescence"],
    ["β-catenin (CTNNB1) activating mutations", "~40%", "Activate Wnt signalling → promote proliferation"],
    ["TP53 inactivating mutations", "Up to 60%", "Loss of cell cycle arrest and apoptosis"],
    ["CDKN2A (p16) loss", "Variable", "Loss of G1/S checkpoint"],
    ["Aflatoxin → TP53 codon 249 hotspot", "Endemic regions", "Arg→Ser transversion — specific molecular signature"],
    ["DNAJB1::PRKACA fusion (fibrolamellar)", "~100% of fibrolamellar HCC", "Excessive protein kinase A activity"],
]
story.append(make_table(mol_data[0], mol_data[1:], col_widths=[5.8*cm, 2.5*cm, 6.5*cm]))

story.append(h2("Gross Morphology — Three Patterns"))
story.append(bullet("<b>Unifocal (usually large) mass:</b> Most common; may replace an entire lobe; pale yellow (fatty change) or green (bile production)"))
story.append(bullet("<b>Multifocal, widely distributed nodules</b> of variable size — intrahepatic metastases from vascular invasion"))
story.append(bullet("<b>Diffusely infiltrative:</b> Permeates widely through liver; may involve entire liver; may mimic cirrhosis grossly"))
story.append(sp(3))
story.append(bullet("Tumours >2 cm: likely vascular invasion and intrahepatic metastases"))
story.append(bullet("<b>Portal vein invasion:</b> Snake-like tumour thrombus → portal hypertension"))
story.append(bullet("Extension into inferior vena cava and right ventricle in advanced cases"))
story.append(sp(4))

story.append(h2("Microscopic Morphology — Histological Grades"))
grade_data = [
    ["Grade", "Key Features"],
    ["Well-differentiated", "Cells closely resemble hepatocytes; thick trabeculae (2–3 cell plates) or pseudoglandular/acinar pattern; bile plugs in pseudoacini; mild nuclear atypia"],
    ["Moderately differentiated", "Recognisable hepatocytes; more nuclear atypia; mitoses present; vascular invasion may be seen"],
    ["Poorly differentiated / Anaplastic", "Marked nuclear pleomorphism; giant cells; frequent mitoses; may lose hepatocellular differentiation; spindle cell areas"],
]
story.append(make_table(grade_data[0], grade_data[1:], col_widths=[3.5*cm, 11.3*cm]))
story.append(sp(4))

story.append(h3("Histological Growth Patterns"))
story.append(bullet("<b>Trabecular (sinusoidal):</b> Most common; thickened liver cell plates separated by sinusoids lined by flat endothelium"))
story.append(bullet("<b>Pseudoglandular (acinar):</b> Dilated bile canaliculi form pseudoacini; bile plugs present — characteristic of HCC"))
story.append(bullet("<b>Solid/compact:</b> Sheets of cells with minimal sinusoidal stroma"))
story.append(bullet("<b>Scirrhous:</b> Prominent fibrous stroma (must be distinguished from cholangiocarcinoma)"))
story.append(sp(4))

story.append(h3("Immunohistochemistry"))
ihc_data = [
    ["Marker", "Sensitivity / Specificity", "Notes"],
    ["HepPar-1", "High specificity", "Most widely used hepatocellular marker"],
    ["Glypican-3 (GPC3)", "Sensitive, esp. well-diff HCC", "Negative in normal hepatocytes and benign lesions"],
    ["Arginase-1", "Highly sensitive and specific", "Best single marker for hepatocellular differentiation"],
    ["AFP (tumour cells)", "Correlates with serum AFP", "Especially in poorly differentiated HCC"],
    ["Polyclonal CEA (pCEA)", "Canalicular pattern", "Bile canalicular staining pattern is specific for HCC"],
]
story.append(make_table(ihc_data[0], ihc_data[1:], col_widths=[3.8*cm, 4.5*cm, 6.5*cm]))

# ── FIBROLAMELLAR ────────────────────────────────────────────────────────
story.append(h2("The Fibrolamellar Variant — Distinct Clinicopathological Entity"))
story.append(body(
    "A special subtype of HCC with entirely different epidemiology, molecular biology, and prognosis from conventional HCC."))
story.append(sp(3))

fl_data = [
    ["Feature", "Detail"],
    ["Age/Demographics", "Adolescents and young adults (median age ~25 yrs); equal sex distribution"],
    ["Liver background", "NO pre-existing liver disease or cirrhosis"],
    ["Serum AFP", "Normal — NOT elevated (unlike conventional HCC)"],
    ["Molecular hallmark", "DNAJB1::PRKACA fusion gene → excessive protein kinase A activity"],
    ["Gross", "Large, well-demarcated nodule; often with a central scar (may mimic FNH)"],
    ["Micro: Triad", "1. Large polygonal cells with granular eosinophilic cytoplasm (abundant mitochondria — oncocytic)\n2. Vesicular nuclei with a single large prominent nucleolus\n3. Parallel lamellae of dense collagen (lamellar fibrosis) separating tumour cells"],
    ["Prognosis", "BETTER than conventional HCC — up to 40% survive 10 years; extensive surgical resection possible"],
]
story.append(make_table(fl_data[0], fl_data[1:], col_widths=[4.5*cm, 10.3*cm]))

# ── VI. CLINICAL FEATURES HCC ─────────────────────────────────────────────
story.append(PageBreak())
story.append(h1("VI. CLINICAL FEATURES OF HCC"))
story.append(h2("Symptoms"))
story.append(bullet("Upper abdominal pain, malaise, fatigue, weight loss, awareness of abdominal mass"))
story.append(bullet("Jaundice and ascites (due to underlying cirrhosis or portal vein invasion)"))
story.append(bullet("Haemoperitoneum from spontaneous tumour rupture (especially sub-Saharan Africa)"))
story.append(sp(4))

story.append(h2("Paraneoplastic Syndromes"))
story.append(bullet("Hypoglycaemia (insulin-like activity)"))
story.append(bullet("Erythrocytosis (ectopic erythropoietin production)"))
story.append(bullet("Hypercalcaemia"))
story.append(bullet("Hypercholesterolaemia"))
story.append(sp(4))

story.append(h2("Laboratory Findings"))
lab_data = [
    ["Test", "Finding / Significance"],
    ["Serum AFP", "Elevated in ~50% of advanced HCC; NOT sensitive for early disease; NORMAL in fibrolamellar variant"],
    ["AST, ALT", "May be elevated or normal"],
    ["ALP", "May be elevated"],
    ["GGT", "Often elevated"],
    ["LDH", "Often elevated in advanced HCC"],
]
story.append(make_table(lab_data[0], lab_data[1:], col_widths=[4.0*cm, 10.8*cm]))
story.append(sp(4))

story.append(h2("Imaging Hallmark"))
story.append(body(
    "<b>Contrast-enhanced CT/MRI:</b> <b>Arterial phase enhancement</b> of HCC (due to high arterialization) "
    "followed by rapid venous <b>washout</b> — this pattern is pathognomonic for HCC and may preclude the need for biopsy. "
    "The <b>LI-RADS</b> scoring system is used for standardised radiological reporting in high-risk patients."))
story.append(sp(4))

story.append(h2("Prognosis and Treatment"))
prog_data = [
    ["Stage / Treatment", "5-year Survival / Notes"],
    ["Confined to liver (small, resectable)", "~30–40%"],
    ["Extrahepatic spread", "~5%"],
    ["Fibrolamellar variant", "Up to 40% at 10 years"],
    ["Surgical resection", "Curative; requires adequate liver reserve; preferred for non-cirrhotic liver"],
    ["Liver transplantation", "For HCC in advanced cirrhosis; Milan criteria: single ≤5 cm or ≤3 lesions each ≤3 cm, no vascular invasion"],
    ["Radiofrequency/microwave ablation", "Unresectable small tumours; tumours not meeting transplant criteria"],
    ["TACE (chemoembolisation)", "Exploits HCC arterialization; local control for unresectable tumours"],
    ["Sorafenib", "Kinase inhibitor; prolongs survival in advanced HCC (palliative)"],
    ["Atezolizumab + Bevacizumab", "Current first-line systemic therapy (immune checkpoint inhibitor combination)"],
]
story.append(make_table(prog_data[0], prog_data[1:], col_widths=[5.5*cm, 9.3*cm]))
story.append(sp(4))

story.append(h2("Causes of Death"))
story.append(bullet("Cachexia (most common in non-cirrhotic HCC)"))
story.append(bullet("GI / oesophageal variceal haemorrhage"))
story.append(bullet("Liver failure / hepatic coma"))
story.append(bullet("Tumour rupture with haemoperitoneum (less common; dramatic presentation)"))

# ── VII. COMPARATIVE TABLE ────────────────────────────────────────────────
story.append(PageBreak())
story.append(h1("VII. COMPREHENSIVE COMPARATIVE TABLE"))
story.append(sp(4))

comp_data = [
    ["Feature", "Regen. Nodule", "FNH", "HCA", "LGDN", "HGDN", "HCC"],
    ["Liver background", "Cirrhotic", "Normal", "Normal", "Cirrhotic", "Cirrhotic", "Cirrhotic (85%)"],
    ["Central scar", "No\n(septa)", "Yes —\npathognomonic", "No", "No", "No", "No"],
    ["Portal tracts", "Present", "Absent in nodule", "Absent", "Reduced", "Absent", "Absent"],
    ["Bile ducts", "Present", "Ductular rxn", "Absent", "Reduced", "Absent", "Absent"],
    ["Arteries", "Normal\n(paired)", "Thick-walled\ncentral", "Unpaired", "Slight ↑", "Increased\nunpaired", "Markedly ↑"],
    ["Cell plates", "1–2 cells", "1–2 cells", "1–2 cells", "1–2 cells", "2–3 cells", ">3 cells"],
    ["Cytologic atypia", "None", "None", "Mild–mod", "Mild", "Moderate–\nmarked", "Moderate–\nmarked"],
    ["AFP (serum)", "Normal", "Normal", "Normal", "Normal", "Normal/↑", "Elevated\n(50–60%)"],
    ["Malignant risk", "None", "None", "Low–mod\n(β-cat: high)", "Low", "High", "N/A\n(malignant)"],
    ["Treatment", "Manage\ncirrhosis", "Conservative", "Resect if\n≥5cm/high risk", "Surveillance", "Close\nf/u or resect", "Resect /\nTransplant"],
]
story.append(make_table(comp_data[0], comp_data[1:],
    col_widths=[3.2*cm, 2.0*cm, 2.0*cm, 2.0*cm, 2.0*cm, 2.0*cm, 1.6*cm]))

story.append(sp(20))
story.append(hr())
story.append(Paragraph(
    "Sources: Robbins, Cotran &amp; Kumar — Pathologic Basis of Disease (9780443264528) · "
    "Robbins &amp; Kumar Basic Pathology (9780323790185) · Harrison's Principles of Internal Medicine 22E",
    SOURCE))

# ── BUILD ──────────────────────────────────────────────────────────────────
def on_page(canvas, doc):
    canvas.saveState()
    canvas.setFont('Helvetica', 7.5)
    canvas.setFillColor(colors.HexColor('#888888'))
    canvas.drawString(2*cm, 1.3*cm, "Orris Medical Education | Pathology of Hepatocellular Nodules")
    canvas.drawRightString(A4[0] - 2*cm, 1.3*cm, f"Page {doc.page}")
    canvas.restoreState()

doc.build(story, onFirstPage=on_page, onLaterPages=on_page)
print(f"PDF created: {OUTPUT}")
Running Command

cd /home/daytona/workspace/liver-pathology && python generate_pdf.py

Running Command

ls -lh /home/daytona/workspace/liver-pathology/Hepatocellular_Nodules_Pathology.pdf

Your PDF is ready. Click to download:

Hepatocellular Nodules Pathology

PDF Document · PDF

What's included (4 pages, A4, colour-coded):
  • Nodular spectrum overview table - all stages from regenerative nodule → HCC
  • Regenerative nodules - cirrhotic nodules, large cell change, small cell change
  • FNH - pathogenesis, gross/micro morphology, distinguishing features
  • Hepatocellular Adenoma - 4 molecular subtypes with risk stratification table
  • Dysplastic nodules - LGDN vs HGDN comparison table; nodule-in-nodule concept
  • HCC - epidemiology, risk factors, molecular biology, gross/micro morphology, growth patterns, IHC markers
  • Fibrolamellar variant - full characterisation table
  • Clinical features, lab findings, imaging hallmark, prognosis, treatment tables
  • Master comparative table spanning all nodule types side-by-side
This is a shared conversation. Sign in to Orris to start your own chat.